Details of the Drug Reposition

General Information of This Drug (ID: DMGECIJ)

Drug Name
Blinatumomab   DMGECIJ
Synonyms AMG 103; Blincyto
Drug Type
Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute lymphoblastic leukaemia DIS87TGM 2A85 Approved [1]
B-cell acute lymphoblastic leukaemia DISKLOKC 2B33.3 Approved [2]
------------------------------------------------------------------------------------
1 Phase 2/3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Diffuse large B-cell lymphoma DISSACK3 2A81 Phase 2/3 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
2 Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. Hum Vaccin Immunother. 2019;15(3):594-602.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)